Physician profile
Thomas C Garner
NPI 1801185442
$12,850.51
in general payments reported to CMS, 2019-2025
57 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,799 · 2020: $1,914 · 2021: $2,123 · 2022: $1,735 · 2023: $1,696 · 2024: $1,643 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,278.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,193.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,323.66 | 2020-2025 | |
| Lilly USA, LLC | $1,068.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $998.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $946.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $603.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $499.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $422.85 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $368.76 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $341.53 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.97 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.03 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $219.17 | 2019-2024 | Spravato, Xarelto |
| Allergan, INC. | $210.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.98 | 2019-2024 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.